Mounjaro®
Starting from £179.99/mo
Start journey Learn moreNo — semaglutide (Wegovy) is a once-weekly injection, and injecting it twice in seven days is not safe or effective. The medicine is designed with a half-life that keeps it active for a full week; giving a second dose before that window closes does not increase weight loss and meaningfully raises your risk of side effects. If you feel your current dose isn't working, the right step is talking to your prescriber, not changing your injection frequency. These are prescription-only medicines, and any adjustment to how or when you use them needs to happen under clinical supervision.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The question comes up more often than you might expect. A few weeks in, someone notices their appetite returns a day or two before their next injection is due. It feels logical to top up. But semaglutide doesn't work like a painkiller you reach for when symptoms return, it maintains a continuous plasma level across seven days, and that sustained presence is precisely what drives appetite suppression and the metabolic effects that produce weight loss.
Injecting a second dose before the week is up doesn't fill a gap; it stacks on top of medicine that is still active in your body. The result is a sharp increase in GLP-1 receptor stimulation that the gastrointestinal system, in particular, is not designed to handle. The NHS's patient-facing guidance on semaglutide is clear that this is a once-weekly injection, with doses taken on the same day each week. There is no licensed variation on that schedule.
If appetite does creep back before injection day, that is worth raising with your prescriber. It may point to the right time for a dose increase through the titration ladder, something that happens in planned, assessed steps, not by self-adjusting frequency. Our prescribers at the nume clinical team field exactly this kind of question in aftercare reviews every week.
Doubling up isn't harmless. The side-effect profile of semaglutide is predominantly gastrointestinal, nausea, vomiting, diarrhoea, and reflux are the most commonly reported effects, and they are dose-dependent. Pushing the effective dose above what your body has been gradually titrated to accept removes the protective logic of the slow escalation schedule entirely.
More seriously, the MHRA has flagged acute pancreatitis as a known, if infrequent, serious side effect of GLP-1 medicines. Taking semaglutide more often than prescribed creates an unpredictable pharmacological picture that makes monitoring and management significantly harder for any clinician trying to help you. The right place to report unexpected effects from any licensed medicine is the MHRA's Yellow Card scheme.
There is also a practical storage point worth knowing. Once removed from the fridge and in use, a Wegovy pen has a finite room-temperature window before the medicine degrades, always check the Patient Information Leaflet for the exact figure. Treating a pen as a reservoir to dip into across a week, rather than a once-weekly single dose, risks both clinical and stability problems. For how long an opened pen remains usable under refrigeration, the detail is covered on our page about semaglutide storage in the fridge.
Wegovy's dosing pathway runs from 0.25 mg up through 0.5 mg, 1.0 mg, 1.7 mg, and 2.4 mg, with roughly four weeks at each level. The MHRA also approved a higher 7.2 mg maintenance dose in 2026 for eligible patients. Each step is a deliberate pause, giving the gut receptors time to adapt, keeping tolerability manageable, and letting the prescriber confirm the patient is responding well before moving up.
That structure is the clinically validated route to more effect from semaglutide. Trying to shortcut it by injecting more frequently bypasses the logic that makes the titration both safe and effective. If you're wondering whether Wegovy is working as expected, a more useful comparison is what the clinical trial data says about realistic timelines: the STEP 1 trial, published in the New England Journal of Medicine, reported around 15% average weight reduction over 68 weeks at the 2.4 mg maintenance dose, a number built on sustained, consistent weekly dosing, not accelerated schedules. You can find a fuller picture of how the injection itself works on our semaglutide weekly injection page.
For a practical guide to technique (injection sites, rotation, and what the pen looks and feels like when it arrives (it comes in a plain, unbranded box via tracked DPD delivery)) the how to inject semaglutide page covers the full process. And if your question is specifically about Wegovy's schedule versus other products, understanding how Ozempic and Wegovy differ is a common follow-up worth reading.
There are a handful of situations where timing does matter and where your prescriber's input is genuinely useful: you forgot your injection and are unsure whether to take it late, your injection day needs to shift permanently, or you feel the current dose stopped producing results weeks ago. None of these are situations where self-adjusting frequency is the safe path, but all of them are routine conversations for a clinical review.
It's also worth separating the question of frequency from the question of what Wegovy costs across a treatment course. If you're weighing up whether continuing makes financial sense, our Wegovy pricing page sets out what private treatment involves honestly, including what one transparent price actually covers. The licensed indication and eligibility criteria for Wegovy are detailed on the Wegovy overview page. If a formal clinical conversation is what you need, starting a free consultation puts your situation in front of a GPhC-registered prescriber the same day.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.